Given the role of CTGF in various fibrotic diseases, such as pulmonary fibrosis, cardiac fibrosis, and systemic sclerosis, there is significant potential for these ASOs to be adapted for treating other fibrotic conditions (Toda et al., 2018; Fu et al., 2022; Qiu et al., 2024). This evidence concerns the gene CCN2 and pulmonary fibrosis.